UK asks: which prescription drugs are least likely to be falsified?
This article was originally published in Scrip
Executive Summary
Which prescription medicines are least likely to be falsified, and which non-prescription drugs are most at risk? That's what the UK regulator, the MHRA, would like to know as it prepares to draw up its proposed "black" and "white" lists of products that in future either should or should not carry the "safety feature" required by the EU falsified medicines Directive (FMD).
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.